From: An assessment of canine ectoparasiticide administration compliance in the USA
Doses purchased | Fluralanera (n = 170,792) | Afoxolaner (n = 248,393) | Sarolaner (n = 70,916) | Lotilaner (n = 16,536) |
---|---|---|---|---|
One dose (Total n, % of total) | 92,153 (54%) | 96,151 (39%) | 22,416 (32%) | 7401 (45%) |
Two to 12 doses (%) | (46%) | (61%) | (68%) | (55%) |
Total purchasing > 1 dose | 78,639 | 152,242 | 48,500 | 9135 |
No gap (n, %) | 27,435 (35%) | 104,945 (69%) | 28,078 (58%) | 5587 (61%) |
Purchase gap (n, %) | 51,204 (65%) | 47,297 (31%) | 20,422 (42%) | 3548 (39%) |
Purchased ≥ 2 doses | 78,639 | 152,242 | 48,500 | 9135 |
Total with 1–2 dose gap (%) | 42,638 (54%) | 28,527 (19%) | 11,049 (23%) | 2041 (22%) |
Average gap (weeks) | 12.8 | 12.9 | 20.3 | 8.9 |
Purchased ≥ 3 doses | 31,241 | 111,420 | 39,695 | 6426 |
Total with 2–3 dose gap (n, %) | 17,543 (56%) | 11,753 (11%) | 6040 (15%) | 1214 (19%) |
Average gap (weeks) | 8.5 | 9.9 | 16.4 | 6.5 |
Purchased ≥ 4 doses | 11,742 | 81,992 | 29,184 | 4943 |
Total with 3–4 dose gap (n, %) | 4206 (36%) | 12,100 (15%) | 5641 (19%) | 731 (15%) |
Average gap (weeks) | 4.8 | 10.1 | 17.6 | 6.4 |
Purchased ≥ 5 doses | 1631 | 69,702 | 25,583 | 4271 |
Total with 4–5 dose gap (n, %) | 457 (28%) | 4389 (6%) | 2416 (9%) | 436 (10%) |
Average gap (weeks) | 3.3 | 7.0 | 12.9 | 4.4 |
Purchased ≥ 6 doses |  | 65,205 | 23,721 | 3912 |
Total with 5–6 dose gap (n, %) |  | 2455 (4%) | 1344 (6%) | 230 (6%) |
Average gap (weeks) | Â | 5.7 | 10.7 | 4.0 |
Purchased ≥ 7 doses |  | 31,598 | 10,020 | 1862 |
Total with 6–7 dose gap (n, %) |  | 5868 (19%) | 4187 (42%) | 421 (23%) |
Average gap (weeks) | Â | 9.1 | 19.4 | 9.8 |
Purchased ≥ 8 doses |  | 22,302 | 7136 | 1416 |
Total with 7–8 dose gap (n, %) |  | 1246 (6%) | 608 (9%) | 114 (8%) |
Average gap (weeks) | Â | 4.3 | 8.8 | 3.9 |
Purchased ≥ 9 doses |  | 18,415 | 5876 | 1172 |
Total with 8–9 dose gap (n, %) |  | 703 (4%) | 334 (6%) | 62 (5%) |
Average gap (weeks) | Â | 3.4 | 8.6 | 3.1 |
Purchased ≥ 10 doses |  | 14,734 | 4495 | 972 |
Total with 9–10 dose gap (n, %) |  | 510 (4%) | 332 (7%) | 35 (4%) |
Average gap (weeks) | Â | 3.4 | 10.3 | 4.0 |
Purchased ≥ 11 doses |  | 13,213 | 3892 | 865 |
Total with 10–11 dose gap (n, %) |  | 137 (1%) | 74 (2%) | 14 (2%) |
Average gap (weeks) | Â | 2.3 | 6.9 | 2.6 |
Purchased 12 doses | Â | 12,044 | 3478 | 770 |
Total with 11–12 dose gap (n, %) |  | 32 (0.3%) | 16 (0.5%) | 7 (1%) |
Average gap (weeks) | Â | 2.1 | 3.6 | 1.6 |